Intellia Therapeutics (NTLA)

Intellia Therapeutics (NTLA) Stock Price & Analysis


NTLA Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$32.44 - $76.45
Previous Close$39.22
Average Volume (3M)1.11M
Market Cap
Enterprise Value$2.65B
Total Cash (Recent Filing)$933.54M
Total Debt (Recent Filing)$126.13M
Price to Earnings (P/E)-7.3
Aug 03, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.39
Shares Outstanding88,140,978
10 Day Avg. Volume1,059,277
30 Day Avg. Volume1,109,524
Standard Deviation0.24
Financial Highlights & Ratios
Price to Book (P/B)3.09
Price to Sales (P/S)272.55
Price to Cash Flow (P/CF)-8.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue49.55
Enterprise Value/Gross Profit50.83
Enterprise Value/Ebitda-8.42
Price Target Upside103.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Intellia Therapeutics’s price range in the past 12 months?
Intellia Therapeutics lowest stock price was $32.44 and its highest was $76.45 in the past 12 months.
    What is Intellia Therapeutics’s market cap?
    Currently, no data Available
    When is Intellia Therapeutics’s upcoming earnings report date?
    Intellia Therapeutics’s upcoming earnings report date is Aug 03, 2023 which is in 68 days.
      How were Intellia Therapeutics’s earnings last quarter?
      Intellia Therapeutics released its earnings results on May 04, 2023. The company reported -$1.17 earnings per share for the quarter, beating the consensus estimate of -$1.4 by $0.23.
        Is Intellia Therapeutics overvalued?
        According to Wall Street analysts Intellia Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Intellia Therapeutics pay dividends?
          Intellia Therapeutics does not currently pay dividends.
          What is Intellia Therapeutics’s EPS estimate?
          Intellia Therapeutics’s EPS estimate is -$1.32.
            How many shares outstanding does Intellia Therapeutics have?
            Intellia Therapeutics has 88,140,976 shares outstanding.
              What happened to Intellia Therapeutics’s price movement after its last earnings report?
              Intellia Therapeutics reported an EPS of -$1.17 in its last earnings report, beating expectations of -$1.4. Following the earnings report the stock price went up 13.142%.
                Which hedge fund is a major shareholder of Intellia Therapeutics?
                Among the largest hedge funds holding Intellia Therapeutics’s share is ARK Investment Management LLC. It holds Intellia Therapeutics’s shares valued at 367M.


                  Intellia Therapeutics Stock Smart Score

                  The Intellia Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Intellia Therapeutics

                  Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.


                  Top 5 ETFs holding NTLA

                  Market Value
                  Smart Score
                  ARK Genomic Revolution ETF
                  Vanguard Health Care ETF
                  iShares NASDAQ US Biotechnology UCITS ETF
                  Fidelity MSCI Health Care Index ETF
                  Vanguard ESG U.S. Stock ETF
                  Up to five ETFs with an Outperform Smart Score that hold NTLA. The ETFs are listed according to market value of NTLA within the ETF


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Cerevel Therapeutics Holdings
                  Denali Therapeutics

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis